Cargando…

Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report

Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder of unknown etiology and characterized by various clinical manifestations and multiple organ involvement. It has been reported in association with POEMS syndrome and can progress to Kaposi's sarcoma or malignant l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Zhen-gang, Dun, Xiao-yi, Li, Yong-hua, Hou, Jian
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686727/ https://www.ncbi.nlm.nih.gov/pubmed/19400935 http://dx.doi.org/10.1186/1756-8722-2-19

Ejemplares similares

Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease
por: Lin, Q, et al.
Publicado: (2015)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Idiopathic multicentric castleman’s disease mimicking immunoglobulin G4-related disease responding well to Bortezomib: a case report
por: Peng, Qian, et al.
Publicado: (2023)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Multicentric Castleman's disease: a case report
por: Menezes, Brian F, et al.
Publicado: (2007)

Multicentric Castleman's disease: Report of three cases
por: Guazzaroni, M., et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
por: Lin, MaoFang, et al.
Publicado: (2014)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
por: Zhou, Pan, et al.
Publicado: (2022)

Multicentric Castleman disease with TAFRO syndrome and Sjögren's
por: Li, Zi Ying, et al.
Publicado: (2019)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
por: Chen, Wendong, et al.
Publicado: (2016)

HIV-associated multicentric Castleman's disease
por: Naime, Fauzia de Fátima, et al.
Publicado: (2012)

Multicentric Castleman disease and the evolution of the concept
por: Zhou, Ting, et al.
Publicado: (2021)

Solamargine induces autophagy‐mediated apoptosis and enhances bortezomib activity in multiple myeloma
por: Han, Qiaoyan, et al.
Publicado: (2022)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
por: Richard, Shambavi, et al.
Publicado: (2021)

Guillain-Barré syndrome in a patient with multiple myeloma after bortezomib therapy: A case report
por: Xu, Yu-Ling, et al.
Publicado: (2019)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

Complete Atrioventricular Block Secondary to Bortezomib Use in Multiple Myeloma
por: Lee, Won-Seop, et al.
Publicado: (2011)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
por: Kosmidis, Christoforos S., et al.
Publicado: (2022)

Bortezomib-Induced Perimyocarditis in a Multiple Myeloma Patient: A Case Report
por: Alali, Yaman, et al.
Publicado: (2021)

Multicentric Castleman Disease of the Supraglottis: A Surgeons’ Dilemma
por: Jumaat, Anna Fariza, et al.
Publicado: (2023)

Updates on the diagnosis and management of multicentric Castleman disease
por: Wu, Ya-Ju, et al.
Publicado: (2020)

Multicentric Castleman disease with infiltration of eosinophils to the lung
por: Nakai, Shogo, et al.
Publicado: (2021)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
por: Painuly, Utkarsh, et al.
Publicado: (2013)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015)

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment
por: Gu, Chunyan, et al.
Publicado: (2015)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
por: Starheim, K K, et al.
Publicado: (2016)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria
por: Korubo, Kaladada I., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bcni556l6rrg07tq0v4c2fhmhg